A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of an Adeno-associated Viral Vector Containing an Expression Cassette of the Human Factor VIII Transgene (BBM-H803) Injection in Participants With Hemophilia A
Latest Information Update: 07 Apr 2026
At a glance
- Drugs BBM H803 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Sponsors Belief Biomed; Shanghai Xinzhi BioMed
Most Recent Events
- 17 Mar 2026 Planned number of patients changed from 12 to 55.
- 17 Mar 2026 Planned End Date changed from 30 Jun 2030 to 30 May 2031.
- 17 Mar 2026 Planned primary completion date changed from 30 Jun 2026 to 30 May 2027.